# ONESOURCE (ONESOURCE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/onesource

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,596.5
- Change: +1.04%
- As of: 2026-09-18
- 1D return: +0.94%
- 5D return: +3.44%
- 1M return: +3.94%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, ONESOURCE is trading at ₹1594.9, with a daily technical stance indicating a potential shift. While the daily timeframe shows the price above several key moving averages (EMA 20, EMA 50, SMA 20, SMA 200, SMA 50), the Supertrend indicator is bearish, suggesting short-term caution. This contrasts with the weekly timeframe, where the Supertrend is bullish, though the price is below its EMA 20, EMA 50, SMA 20, and SMA 50. The monthly timeframe presents a mixed picture, with the price above its EMA 20 but below its SMA 20 and Supertrend, which is also bearish. Recent market activity includes two positive attention events and one neutral event in the last 30 days, alongside an upward gap on September 15, 2026. The stock is currently positioned within its recent trading range, closer to the lower end based on 50-day and 252-day ranges.

The nearest support level is identified at ₹1590.47, approximately 0.28% below the current price. Resistance is observed at ₹1611.33, about 1.03% higher. The stock exhibits an annualized volatility of 44% and a current drawdown of -27%. A notable anomaly occurred on September 9, 2026, with extreme volume accompanying a price decrease, and another on September 8, 2026, with extreme volume and a price increase. A "Harami" pattern was active on the monthly timeframe as of September 18, 2026.

Key watch conditions include monitoring the price action around the ₹1590.47 support level. A break below this could signal further downside. Conversely, a sustained move above the ₹1611.33 resistance level, especially with increasing volume, would be a positive development. The conflicting signals between the daily and longer-term timeframes suggest a period of consolidation or transition, making close observation of price action crucial.

- Current price on September 18, 2026: ₹1594.9.
- Nearest support level: ₹1590.47 (approx. 0.28% below current price).
- Nearest resistance level: ₹1611.33 (approx. 1.03% above current price).
- Daily timeframe shows price above key moving averages but a bearish Supertrend.
- Weekly timeframe shows a bullish Supertrend, but price is below key moving averages.
- Monthly timeframe shows a bearish Supertrend and price below SMA 20.
- Watch for price movement around ₹1590.47 support and ₹1611.33 resistance.

- Harami
- Bearish Engulfing Reversal
- Doji
- Shooting Star
- Morning Star
- Inside Bar

### News Context

Onesource Specialty Pharma Limited provided updates regarding its upcoming 19th Annual General Meeting (AGM) scheduled for September 23, 2026. An addendum to the AGM notice, issued on September 11, 2026, disclosed additional details on material related party transactions with Strides Pharma Science Limited and its US subsidiary, specifically concerning agenda items 6 and 7. The company also confirmed that the Audit Committee has reviewed the necessary CEO/CFO certificates for these transactions. Earlier, on September 1, 2026, Onesource Specialty Pharma announced the publication of newspaper advertisements confirming the dispatch of the AGM notice and remote e-voting information. The company's 19th AGM will review the Integrated Annual Report for the financial year ending March 31, 2026, during which the company reported revenue of ₹14,216 million and adjusted profit after tax of ₹739 million. Additionally, Onesource Specialty Pharma committed approximately US$80 million towards expanding its cartridge manufacturing capacity as part of a planned US$100 million capital expenditure program and received in-principle approval for incentives worth approximately ₹70 crore under the Karnataka Industrial Policy 2025–30. The company also completed a statutory auditor rotation, appointing BSR (KPMG) to replace Deloitte.

In parallel, Onesource Specialty Pharma engaged with investors, holding an investor presentation on September 3, 2026, at its manufacturing facility in Doddaballapura, Bengaluru. This event followed a scheduled physical group investor meeting on the same date, where representatives discussed publicly available information on business overview, strategy, and industry trends. The company uploaded its latest investor presentation to its website following these engagements.

- On September 11, 2026, Onesource Specialty Pharma issued an addendum to its 19th AGM notice, detailing material related party transactions with Strides Pharma Science Limited.
- The company reported FY26 revenue of ₹14,216 million and adjusted profit after tax of ₹739 million, as detailed in the notice for the 19th AGM scheduled for September 23, 2026.
- Onesource Specialty Pharma committed approximately US$80 million to expand cartridge manufacturing capacity and received in-principle approval for ₹70 crore in industrial incentives.
- The company completed a statutory auditor rotation, with BSR (KPMG) replacing Deloitte.
- Investor engagements included a presentation and a physical group meeting on September 3, 2026, at the company's Bengaluru manufacturing facility.

- Onesource Specialty Pharma Limited has informed the Exchange regarding 'Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026 |SUBJECT: Updates
- Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation
- Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication confirming dispatch of Notice of the 19th Annual GeneralMeeting (AGM) and Remote e-voting |SUBJECT: Copy of Newspaper Publication
- Onesource Specialty Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026 |SUBJECT: Shareholders meeting

### What Changed

As of September 18, 2026, Onesource Specialty Pharma (NSE: ONESOURCE) saw a modest increase in its stock price, moving from ₹1580.0 to ₹1594.9. This change occurred on the observation date of September 18, 2026. No new filings or news developments were reported for the company in the period leading up to this date. The company's profile on the NSE remains unchanged.

- On September 18, 2026, the stock price of Onesource Specialty Pharma was ₹1594.9.
- The previous recorded stock price for Onesource Specialty Pharma was ₹1580.0.
- No new filings or news were reported for Onesource Specialty Pharma as of September 18, 2026.

### Official Filings

OneSource Specialty Pharma Limited has provided updates regarding its upcoming 19th Annual General Meeting (AGM) scheduled for September 23, 2026. An addendum to the AGM notice, filed on September 11, 2026, disclosed additional information on material related party transactions with Strides Pharma Science Limited and its US subsidiary, pertaining to agenda items 6 and 7. The company also published newspaper advertisements on September 1, 2026, confirming the dispatch of AGM notices and remote e-voting information. Earlier, on August 31, 2026, the company announced its 19th AGM date and provided financial highlights for the fiscal year ending March 31, 2026 (FY26). During FY26, OneSource reported revenue of ₹14,216 million and adjusted profit after tax of ₹739 million. The company committed approximately US$80 million of a planned US$100 million capital expenditure towards expanding cartridge manufacturing capacity and received in-principle approval for incentives worth approximately ₹70 crore under the Karnataka Industrial Policy 2025–30. Additionally, the company completed a statutory auditor rotation from Deloitte to BSR (KPMG). The Business Responsibility & Sustainability Report for FY26, filed on August 31, 2026, detailed a standalone paid-up capital of ₹11.46 crore, a turnover of ₹14,204 million (70.80% from exports), and a workforce of 995 permanent workers and 188 employees as of FY26. Operational metrics included ISO certifications for quality, safety, environment, and information security. On August 17, 2026, India Ratings & Research upgraded the company's long-term bank loan facilities rating to 'IND A' with a positive outlook, reflecting a transition to a commercial supply-led model. The company reported strong Q1 FY27 performance on July 31, 2026, with revenues of INR 4,490 million (up 37% year-on-year) and EBITDA of INR 1,233 million (up 39% year-on-year), driven by a semaglutide launch and nearing completion of its capital expenditure program. Preeti Kalra was designated as Senior Management Personnel effective July 24, 2026, while Ravi Kumar resigned from his SMP position on the same date.

- On September 11, 2026, an addendum to the 19th AGM notice disclosed additional details on material related party transactions with Strides Pharma Science Limited and its US subsidiary.
- The 19th AGM is scheduled for September 23, 2026, where the Integrated Annual Report for FY26 will be reviewed.
- For FY26, OneSource reported revenue of ₹14,216 million and adjusted profit after tax of ₹739 million, with approximately US$80 million of US$100 million capex committed to cartridge capacity expansion.
- On August 17, 2026, India Ratings & Research upgraded the company's long-term bank loan facilities rating to 'IND A' with a positive outlook.
- Q1 FY27 revenues were INR 4,490 million (up 37% YoY) and EBITDA was INR 1,233 million (up 39% YoY), driven by a semaglutide launch.

- Onesource Specialty Pharma Limited has informed the Exchange regarding 'Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026 |SUBJECT: Updates
- Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation
- Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication confirming dispatch of Notice of the 19th Annual GeneralMeeting (AGM) and Remote e-voting |SUBJECT: Copy of Newspaper Publication
- Onesource Specialty Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026 |SUBJECT: Shareholders meeting
- Onesource Specialty Pharma Limited has informed the Exchange regarding 'Intimation of Business Responsibility and Sustainability Report for FY 25-26'. |SUBJECT: Updates
- Onesource Specialty Pharma Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating

### Fundamentals

Onesource Specialty Pharma (NSE) has shown a notable shift in its operating performance, moving from losses to profitability. Revenue from operations increased sequentially, reaching ₹449.02 crore in Q1 FY2026-27 from ₹428.22 crore in Q4 FY2025-26. This revenue growth has coincided with a turnaround in profitability. After reporting losses in Q3 FY2025-26 (₹-88.70 crore Profit Loss For Period) and a marginal profit in Q4 FY2025-26 (₹4.60 crore Profit Loss For Period), the company posted a profit of ₹25 crore for Q1 FY2026-27. This improvement is also reflected in the earnings per share, which moved from a loss of ₹-7.74 per share in Q3 FY2025-26 to ₹2.18 per share in Q1 FY2026-27. The company's ability to translate revenue growth into profit is a key area to monitor, especially given the fluctuating tax expenses observed across the periods.

- Revenue from operations for Onesource Specialty Pharma was ₹449.02 crore in Q1 FY2026-27, up from ₹428.22 crore in Q4 FY2025-26.
- The company reported a Profit Loss For Period of ₹25 crore in Q1 FY2026-27, compared to ₹4.60 crore in Q4 FY2025-26 and a loss of ₹-88.70 crore in Q3 FY2025-26.
- Basic Earnings Loss Per Share from Continuing Operations improved to ₹2.18 per share in Q1 FY2026-27, from ₹0.40 per share in Q4 FY2025-26 and ₹-7.74 per share in Q3 FY2025-26.
- Comprehensive Income For The Period was ₹28.59 crore in Q1 FY2026-27, a significant increase from ₹15.25 crore in Q4 FY2025-26 and ₹-92.13 crore in Q3 FY2025-26.

### Bull Case

The company's stock is showing some constructive signals on a weekly basis, with the Supertrend indicator suggesting a bullish trend as of September 18, 2026. While the daily and monthly trends are currently indicated as bearish, the weekly timeframe indicates potential for upward movement. The stock's closing price of ₹1594.9 is trading above its 20-day Exponential Moving Average (EMA) of ₹1566.21, and the EMA itself is showing a positive slope, which can be interpreted as short-term positive momentum. Additionally, the stock has experienced positive returns over shorter periods, including a 3.0% return in the last month and a 7.7% return over the last six months. However, it is important to note that the stock has experienced a year-to-date return of -11.0% and a 1-year return of -14.0%, indicating a longer-term downward trend. The current price is also approaching a near-term resistance level at ₹1611.33, which is 1.03% above the current price.

- As of September 18, 2026, the weekly Supertrend indicator is bullish.
- The stock's closing price of ₹1594.9 on September 18, 2026, is above its 20-day EMA of ₹1566.21.
- The 20-day EMA has a positive slope, indicating short-term upward momentum.
- The stock has generated a 3.0% return in the last month and an 7.7% return over the last six months.
- A resistance level is identified at ₹1611.33, approximately 1.03% above the current price.

### Bear Case

Onesource Specialty Pharma's technical indicators suggest a cautious outlook. The monthly trend shows a bearish Supertrend at ₹2375.47, indicating a longer-term downward pressure. While the weekly trend has a bullish Supertrend at ₹1355.1, the weekly 20-day and 50-day Simple Moving Averages (SMAs) are sloping downwards, with the 50-day SMA slope at -27.73 and the 20-day SMA slope at -7.86. The stock is trading below its 20-day and 50-day SMAs on a weekly basis. Daily indicators present a mixed picture, with a bearish Supertrend at ₹1650.57, but the 20-day Exponential Moving Average (EMA) slope is positive at 17.0. The stock is currently trading slightly above its 20-day EMA (₹1566.21) and 50-day SMA (₹1589.17), but below its 200-day SMA (₹1581.67). The company has experienced a year-to-date return of -11% and a 1-year return of -14%. Its current drawdown stands at -27%, with a maximum drawdown of -49% observed historically.

- Monthly Supertrend is bearish at ₹2375.47 as of 2026-09-18.
- Weekly 50-day SMA slope is negative at -27.73, and the 20-day SMA slope is negative at -7.86.
- Year-to-date return is -11% and 1-year return is -14% as of 2026-09-18.
- Current drawdown is -27%, with a maximum historical drawdown of -49%.

### FAQs

**What were Onesource Specialty Pharma's key financial results for the fiscal year ending March 31, 2026, and what capital expenditure plans were mentioned?**

For the fiscal year ending March 31, 2026, Onesource Specialty Pharma reported revenue of ₹14,216 million and adjusted profit after tax of ₹739 million. The company also committed approximately US$80 million towards its planned US$100 million capital expenditure program, specifically for expanding cartridge manufacturing capacity.

**What material related party transactions are being discussed at the upcoming 19th Annual General Meeting (AGM)?**

An addendum to the notice for the 19th AGM, scheduled for September 23, 2026, disclosed additional information regarding material related party transactions. These transactions involve Strides Pharma Science Limited and its subsidiary, Strides Pharma Inc, USA, and pertain to Items 6 and 7 of the AGM agenda. The Audit Committee has reviewed the necessary CEO/CFO certificates for these items.

**How has Onesource Specialty Pharma's stock performed over different periods leading up to September 18, 2026?**

As of September 18, 2026, Onesource Specialty Pharma's stock showed mixed performance across different timeframes. It had a 1-month return of 3%, a 6-month return of 8%, and a return since the start of 3%. However, its year-to-date return was -11%, and its 1-year return was -14%.

**What is the current technical trend and what are the nearest support and resistance levels for Onesource Specialty Pharma?**

As of September 18, 2026, the daily trend for Onesource Specialty Pharma indicates a 'bearish' SuperTrend at 1650.57, with the closing price at 1594.9. The weekly trend, however, shows a 'bullish' SuperTrend at 1355.1. The nearest identified support level is 1590.47, and the nearest resistance level is 1611.33.

- Onesource Specialty Pharma Limited has informed the Exchange regarding 'Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026 |SUBJECT: Updates
- Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation
- Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication confirming dispatch of Notice of the 19th Annual GeneralMeeting (AGM) and Remote e-voting |SUBJECT: Copy of Newspaper Publication
- Onesource Specialty Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026 |SUBJECT: Shareholders meeting
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹1,590.47
- Risk regime: Price Risk Requires Attention

### Support levels
- 1541.65625
- 1508.74140625
- 1478

### Resistance levels
- 1645.6
- 1669.53125
- 1752.3953125

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.94% |
| return_10 | +1.22% |
| return_1m | +3.41% |
| return_1y | -14.25% |
| return_20 | +3.94% |
| return_3m | -3.41% |
| return_5 | +3.44% |
| return_6m | +8.38% |
| return_since_start | +3.18% |
| return_ytd | -10.78% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -49.31% |
| annualized_volatility | +43.85% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Climbs 37% as Business Swings to Profit

OneSource Specialty Pharma reported its highest quarterly revenue in the past five quarters and swung from a loss a year ago to a clear profit. Revenue from operations rose 37% to ₹449.02 crore, while profit before tax moved from a loss of ₹4.40 crore to a profit of ₹20.29 crore. The swing reflected revenue growth that outpaced the increase in total costs, though depreciation and finance costs remained large.

## Revenue Growth and Trajectory

Revenue of ₹449.02 crore was the highest in the five-quarter sequence and increased by ₹121.75 crore (37.2%) from ₹327.27 crore in the same quarter last year. Sequentially, revenue grew 4.9% from ₹428.22 crore in the preceding quarter. The quarterly pattern over the past year was uneven: a rise in the second quarter, a sharp drop in the third, a strong recovery in the fourth, and a further increase in the current quarter.

## Profitability Recovery

Profit before tax (PBT) of ₹20.29 crore compares with a loss of ₹4.40 crore a year ago and a near‑breakeven loss of ₹0.29 crore in the immediately preceding quarter. Net profit for the quarter was ₹25.00 crore, against a net loss of ₹0.19 crore in the year‑ago quarter. Basic earnings per share from continuing operations stood at ₹2.18, up from a loss of ₹0.02 per share a year ago.

Tax expense continued to be a credit (negative tax) in every quarter of the five‑quarter series, averaging around ₹4.6 crore per quarter. In the current quarter, the tax credit of ₹4.70 crore lifted net profit above PBT.

Other comprehensive income added ₹3.59 crore to net profit, bringing total comprehensive income to ₹28.59 crore, compared with ₹2.83 crore in the same quarter last year.

## Cost Structure and Operating Leverage

Key expense items for the current quarter relative to revenue of ₹449.02 crore were:

- Cost of materials consumed: ₹141.19 crore (31.4% of revenue)
- Employee benefits: ₹68.68 crore (15.3%)
- Depreciation and amortisation: ₹71.75 crore (16.0%)
- Finance costs: ₹30.81 crore (6.9%)
- Changes in inventories of finished goods and work‑in‑progress: ₹1.13 crore

After including other income of ₹3.80 crore and accounting for other operating expenses, PBT settled at ₹20.29 crore. Revenue growth of 37% outpaced the rise in total costs, enabling the company to return to profitability after the prior‑year loss and the deep loss reported two quarters earlier.

## Finance Costs and Depreciation

Finance costs of ₹30.81 crore were higher than the ₹22.51 crore in the immediate prior quarter and the ₹27.48 crore a year ago. Earlier quarters recorded finance costs of ₹33.96 crore and ₹38.23 crore, reflecting quarter‑to‑quarter variability. Depreciation was ₹71.75 crore, a significant expense consistent with the company’s capital‑intensive CDMO operations. Together, depreciation and finance costs absorbed about 23% of revenue, representing a large fixed‑cost base.

## Key Takeaway

OneSource Specialty Pharma reported a materially stronger quarter, with revenue reaching a new high and profitability recovering from the loss a year ago. The 37% revenue growth supported the earnings swing, as total costs rose more slowly than revenue. Depreciation and finance costs remain substantial; past quarters show that when revenue was lower, the company posted losses, highlighting the sensitivity of profitability to the level of revenue.

### Ratios

## Official filings

- 2026-09-11 — Generic Announcement: Onesource Specialty Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_11092026170521_OS_Addendum_AGM_Notice_11Sep26_s.pdf)
- 2026-09-03 — Earnings Presentation: Onesource Specialty Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_03092026123804_OneSource_Intimation_of_Presentation.pdf)
- 2026-09-01 — Generic Announcement: Onesource Specialty Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_01092026172511_OS_Intimation.pdf)
- 2026-08-31 — Generic Announcement: Onesource Specialty Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_31082026184702_Intimationsigned.pdf)
- 2026-08-31 — Generic Announcement: Onesource Specialty Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_31082026202941_OS_Intimation_19th_AGM_Notice_and_IAR_FY26_S__1_.pdf)
- 2026-08-31 — Generic Announcement: Onesource Specialty Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_31082026223509_OS_Intimation_BRSR_FY26_s.pdf)
- 2026-08-18 — Credit Rating Update: Onesource Specialty Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_18082026131707_OS_Intimation_Credit_Rating_18Aug2026_s.pdf)
- 2026-07-31 — Earnings Transcript: OneSource Specialty Pharma Limited reported Q1 FY27 revenues of INR 4,490 million, a 37% year-on-year increase, and EBITDA of INR 1,233 million, up 39% year-on-year. The company highlighted strong performance driven by the semaglutide commercial launch in Canada and India, new customer wins, and the nearing completion of its US$100 million capex with a second cartridge line set for commercialization. The company reiterated its FY28 outlook of $400 million in organic revenue and 40% EBITDA margins. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_31072026125529_OS_Intimation_Transcript_Earnings_Call_s.pdf)
- 2026-07-27 — Generic Announcement: Preeti Kalra, Head of Human Resources, has been designated as Senior Management Personnel (SMP) effective July 24, 2026. Concurrently, Ravi Kumar, Global Head – Injectables/Head of Corporate Strategy, Portfolio & SPO, has resigned from his SMP position effective July 24, 2026, due to personal reasons. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_27072026190234_OS_Intimation_SMP_changes_270726.pdf)
- 2026-07-26 — Generic Announcement: OneSource Specialty Pharma Limited published newspaper advertisements on July 26, 2026, in the Financial Express and Lokmat, presenting extracts of its un-audited financial results for the quarter ended June 30, 2026. This action complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_26072026230930_OS_Intimation_Newspaper_advertisement_f.pdf)
- 2026-07-25 — Generic Announcement: OneSource Specialty Pharma Limited has made available an audio recording of its earnings call held on July 25, 2026. The call discussed the company's unaudited financial results for the quarter ended June 30, 2026. The recording is accessible on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_25072026150106_Intimation_of_Audio_Recording_of_Earnings_call.pdf)
- 2026-07-24 — Official Filing: ONESOURCE SPECIALTY PHARMA LIMITED allotted 2900 equity shares under ESOP/ESPS on July 24, 2026. The paid-up share capital increased from INR 114,669,991 to INR 114,672,891. The issuance was made prior to the company's listing on recognized stock exchanges.
- 2026-07-24 — Generic Announcement: Deloitte Haskins & Sells has reviewed the unaudited standalone and consolidated financial results of OneSource Specialty Pharma Limited for the quarter ended June 30, 2026. The review concluded that nothing came to their attention to indicate material misstatements or non-disclosure according to SEBI LODR Regulations. The consolidated results include financial information from subsidiaries, some of which were reviewed by other auditors, and some were unaudited but deemed immaterial by management. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_24072026190301_OS_Unaudited_FS_June_30_2026_upload.pdf)
- 2026-07-24 — Press Release: OneSource Specialty Pharma Limited reported strong Q1FY27 results on July 24, 2026, with revenue reaching ₹4,490 million, a 37% year-over-year increase, and EBITDA at ₹1,233 million, up 39% year-over-year. This growth was driven by the semaglutide commercial launch, new MSA contracts, and customer wins. The company reaffirmed its FY28 guidance of $400 million in organic revenue with a 40% EBITDA margin and plans to bring its second cartridge line into commercial operations in Q2 FY27. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_24072026211811_OS_Intimation_PR.pdf)
- 2026-07-24 — Generic Announcement: Preeti Kalra, Head of Human Resources, has been designated as Senior Management Personnel (SMP) effective July 24, 2026. Concurrently, Ravi Kumar, Global Head – Injectables/ Head of Corporate Strategy, Portfolio & SPO, has resigned from his SMP position effective July 24, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_24072026195108_SMP_Changes_intimationsigned.pdf)
- 2026-07-24 — Official Filing: On July 24, 2026, ONESOURCE SPECIALTY PHARMA LIMITED reported a change in senior management personnel following a board meeting. The changes include a modification in the reporting structure, with Ms. Preeti Kalra involved, and the resignation of Mr. Ravi Kumar, both effective on the same date.
- 2026-07-24 — Generic Announcement: On July 24, 2026, OneSource Specialty Pharma Limited approved the allotment of 2,900 equity shares, each with a par value of INR 1, under the ONESOURCE ESOP 2021 to eligible employees. This allotment increased the company's paid-up share capital from INR 11,46,69,991 to INR 11,46,72,891. The newly issued shares rank pari passu with existing equity shares. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_24072026223916_ESOP_Intimation-signed.pdf)
- 2026-07-21 — Generic Announcement: OneSource Specialty Pharma Limited has scheduled an earnings call for Saturday, July 25, 2026, at 10:00 AM IST to discuss the company's unaudited financial results for the quarter ended June 30, 2026. The call will feature CEO & MD Neeraj Sharma and CFO Anurag Bhagania. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_21072026123051_OS_SEI_Earnings_call_21July2026_c.pdf)
- 2026-07-20 — Official Filing: ONESOURCE SPECIALTY PHARMA LIMITED will hold a board meeting on July 24, 2026, to consider unaudited financial results for the quarter ended June 2026. The trading window for the company's securities will be closed from July 1, 2026, to July 26, 2026.
- 2026-07-14 — Generic Announcement: OneSource Specialty Pharma Limited and Formycon AG announced a strategic manufacturing partnership for biosimilars on July 14, 2026. OneSource will provide integrated Drug Substance and Drug Product manufacturing from its Bangalore facility to support Formycon's global biosimilar programs. This collaboration aims to enhance global access to biosimilars through reliable, high-quality, and scalable manufacturing. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_14072026100240_OS_PR_SE_Intimation_14July2026.pdf)
- 2026-07-09 — Generic Announcement: OneSource Specialty Pharma Limited clarified that Dr. Reddy's Laboratories' disclosed delay in commercial supplies of Semaglutide does not materially impact OneSource's operations financially or otherwise. OneSource has sufficient demand from other customers, including for Canada, and its capacities are fully committed. The company is adding new capacities starting the current quarter to meet future demand, including from Dr. Reddy's Laboratories when they are ready. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_09072026104919_OS_SE_Intimation_Reg_30_09July26.pdf)
- 2026-07-08 — Generic Announcement: On July 08, 2026, OneSource Specialty Pharma Limited approved the allotment of 24,190 equity shares of INR 1/- each under its ESOP 2021 plan to eligible employees. This allotment increased the company's paid-up share capital from INR 11,46,45,801/- to INR 11,46,69,991/-. The new shares rank pari passu with existing equity shares. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_08072026184244_OS_Allotment_of_ESOPs_08July2026.pdf)
- 2026-07-02 — Generic Announcement: OneSource Specialty Pharma Limited's Sterile Product Division facility in Bengaluru underwent a routine US-FDA cGMP inspection from June 22 to June 30, 2026. The inspection concluded with one observation, to which the company will provide a comprehensive response to the FDA within the stipulated timeframe. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_02072026161928_OS_SE_intimation_US_FDA_Inspection_02Jul26.pdf)
- 2026-06-24 — Generic Announcement: OneSource Specialty Pharma Limited will close its trading window for dealing in shares from July 01, 2026, until 48 hours after the declaration of financial results for the quarter ended June 30, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/ONESOURCECDMO_24062026182227_1_OS_Window_Closure_Q1FY27.pdf)

## News and market events

- 2026-08-18 — BUSINESS: **Nifty trades tad above 24,200 level; European shares decline** — The benchmark indices continued to trade with limited losses in afternoon trade, weighed down by a rise in crude oil prices following the expiry of the US-Iran ceasefire and growing uncertainty over the reopening of the Strait of Hormuz. The Nifty traded tad above the 24,200 mark. IT, FMCG & metal shares declined while auto, oil & gas and pharma stocks managed to trade in the green. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-trades-tad-above-24-200-level-european-shares-decline-126081800580_1.html)
- 2026-07-14 — Economic Times: **OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars** — OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable global access to life-changing biosimilar therapies. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/onesource-specialty-pharma-partners-with-formycon-ag-to-manufacture-biosimilars/articleshow/132385862.cms)
- 2026-07-14 — CNBC-TV18: **Sensex Today | Stock Market Live Update: Nifty below 24,150; CreditAccess Grameen shares down 4%** — Stock Market Live Update: The market resilience gets put to test yet again today during the weekly options expiry of the Nifty contracts. 24,000 and 23,800 on the downside remain the key levels for the index, while 24,250 - 24,350 on the upside remains a supply zone. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-expiry-today-oil-hpcl-ongc-ril-banks-hcltech-ltts-tata-elxsi-share-price-liveblog-19944620.htm)
- 2026-07-14 — The Hindu: **Sensex today | Stock Market Live: Sensex drops over 370 points; Nifty slips below 24,120** — Sensex, Nifty, Stock Price Live Updates: Indian equity markets traded lower on Tuesday, with the Sensex falling over 500 points, as escalating US-Iran tensions, Brent crude hovering around $85 a barrel, renewed FPI selling and persistent geopolitical uncertainty kept investors cautious despite resilience in broader market segments. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-14th-july-2026/article71217153.ece)

## Business profile

**Strategic vision:** Pharmaceutical and biologic contract development and manufacturing organization.

### Business segments
- **Biologics Development and Manufacturing:** Offers integrated support for complex biologics, including process and analytical development, technology transfer, and scale-up.
- **Drug-Device Combination Solutions:** Specializes in the design, development, and manufacturing of combination products like prefilled syringes, auto-injectors, and pen injectors.
- **Complex Sterile Injectables:** Focuses on formulation and production of advanced sterile dosage forms including sterile liquids, lyophilized vials, cartridges, and pre-filled syringes.
- **Soft Gelatin Capsule Production:** Develops and manufactures high-quality soft gelatin capsules in multiple formats, shapes, and sizes.

### Competitive strengths
- India's first pure-play specialty pharma CDMO.
- Over three decades of operational experience through integrated businesses.
- End-to-end service offering from development to commercial manufacture.
- Expertise in complex biologics, drug-device combinations, and sterile injectables.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/onesource
Markdown representation: https://faxioms.com/stocks/onesource?render=md